| TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients DMS Hossain, SK Pal, D Moreira, P Duttagupta, Q Zhang, H Won, J Jones, ... Clinical Cancer Research 21 (16), 3771-3782, 2015 | 186 | 2015 |
| Control of B cell development by the histone H2A deubiquitinase MYSM1 XX Jiang, Q Nguyen, YC Chou, T Wang, V Nandakumar, P Yates, L Jones, ... Immunity 35 (6), 883-896, 2011 | 104 | 2011 |
| Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia Q Zhang, DMS Hossain, P Duttagupta, D Moreira, X Zhao, H Won, ... Blood, The Journal of the American Society of Hematology 127 (13), 1687-1700, 2016 | 89 | 2016 |
| TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs H Won, D Moreira, C Gao, P Duttagupta, X Zhao, E Manuel, D Diamond, ... Journal of leukocyte biology 102 (2), 423-436, 2017 | 53 | 2017 |
| Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity D Moreira, S Sampath, H Won, SV White, YL Su, M Alcantara, C Wang, ... The Journal of clinical investigation 131 (2), 2021 | 50 | 2021 |
| Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1 H Won, V Nandakumar, P Yates, S Sanchez, L Jones, XF Huang, ... Blood, The Journal of the American Society of Hematology 124 (17), 2647-2656, 2014 | 50 | 2014 |
| Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and/or enzalutamide therapy SK Pal, D Moreira, H Won, SW White, P Duttagupta, M Lucia, J Jones, ... International Journal of Molecular Sciences 20 (8), 1831, 2019 | 43 | 2019 |
| B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors X Zhao, Z Zhang, D Moreira, YL Su, H Won, T Adamus, Z Dong, Y Liang, ... Molecular Therapy 26 (3), 695-707, 2018 | 29 | 2018 |
| Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients S Sampath, H Won, E Massarelli, M Li, P Frankel, N Vora, L Vora, ... Oncotarget 9 (13), 11279, 2018 | 25 | 2018 |
| Mysm1 is required for interferon regulatory factor expression in maintaining HSC quiescence and thymocyte development XF Huang, V Nandakumar, G Tumurkhuu, T Wang, B Hong, L Jones, ... Cell death & disease 7 (6), e2260-e2260, 2016 | 20 | 2016 |
| Association of microbiome and plasma cytokine dynamics to nivolumab response in metastatic renal cell carcinoma (mRCC). MC Maia, V Poroyko, H Won, L Almeida, PG Bergerot, N Dizman, J Hsu, ... Journal of Clinical Oncology 36 (6_suppl), 656-656, 2018 | 12 | 2018 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| Gut microbiome composition and response to sunitinib in metastatic renal cell carcinoma (mRCC). J Gong, N Dizman, V Poroyko, H Won, CD Bergerot, PG Bergerot, ... Journal of Clinical Oncology 36 (6_suppl), 657-657, 2018 | 3 | 2018 |
| Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC). JJ Adashek, H Won, D Moreira, P Duttagupta, P Twardowski, J Jones, ... Journal of Clinical Oncology 37 (7_suppl), 296-296, 2019 | 1 | 2019 |
| Chemo-radiotherapy induces tolerogenic STAT3 signaling in circulating myeloid-derived suppressor cells in patients with head and neck squamous cell carcinoma (HNSCC) H Won, S Sampath, E Massarelli, E Maghami, M Kortylewski Clinical Cancer Research 23 (23_Supplement), 35-35, 2017 | 1 | 2017 |
| 261. Gain-of-Function Effect Augments Therapeutic Efficacy of CpG-STAT3 Anti-Sense Oligonucleotide Against Castration-Resistant Prostate Cancers D Moreira, X Zhao, H Won, P Duttagupta, S Pal, M Kortylewski Molecular Therapy 24, S103, 2016 | 1 | 2016 |
| Myeloid cell-selective STAT3 inhibition sensitizes head and neck cancers to radiation therapy and stimulates T-cell-dependent tumor regression D Moreira, M Kortylewski, S Sampath, H Won, C Wang, P Lee, E Maghami, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Changes in cellular and molecular immune markers in the peripheral blood of patients undergoing chemotherapy and radiation for squamous cell carcinoma of head and neck: A … S Sampath, HJ Won, E Maghami, E Massarelli, N Vora, L Vora, ... Clinical Cancer Research 23 (23_Supplement), 36-36, 2017 | | 2017 |
| Peripheral immunomodulatory changes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab L Almeida, M Maia, H Won, D Moreira, P Bergerot, M Kortylewski, S Pal JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | | 2017 |
| ABIraterone (ABI) and ENZalutamide (ENZ) induce changes in immunologic profile of patients with metastatic castration-resistant prostate cancer (mCRPC) M Salgia, ML Perez, J Jones, HJ Won, V Poroyko, P Twardowski, ... CANCER RESEARCH 77, 2017 | | 2017 |
